Fig. 4: KY19334 treatment improves glucose metabolism and insulin sensitivity in NASH mice. | Experimental & Molecular Medicine

Fig. 4: KY19334 treatment improves glucose metabolism and insulin sensitivity in NASH mice.

From: Metabolic improvement and liver regeneration by inhibiting CXXC5 function for non-alcoholic steatohepatitis treatment

Fig. 4

a–h C57BL/6 mice fed a NCD or HFD + CCl4 were orally administered KY19334, selonsertib, or ocaliva at 25 mg/kg/d for 4 weeks (n = 10 per group). a Relative mRNA expression of Wnt/β-catenin signaling target genes (Tcf7l2, Glp-1, Axin2, Fosl1, and Wisp1) (n = 3). b Serum concentrations of leptin and resistin. c Serum concentration of total cholesterol, HDL-cholesterol, and TGs. d Fasting glucose. e GTT and ITT. f Plasma insulin concentration in the overnight fasted state (top panel) and HOMA-IR (bottom panel). g Representative images of H&E and IHC staining for Ucp1. Scale bars, 100 µm. h Relative mRNA expression of genes that are markers of mitochondria and beige fat (n = 3). Data represent the mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001 determined by Student’s t test.

Back to article page